Is there a difference between biomarker cardiovascular risk assessment for broad population studies vs the role in personalized medicine? And, in individual patients, if a difference is found between the Framingham score and the biomarker risk assessment, which is more likely to correctly predict risk? Host Dr. Alan Brown talks with Dr. Michael Davidson, director of preventive cardiology and associate vice chairman for continuing medical education at the University of Chicago, about the role of biomarkers in improving cardiovascular risk prediction and guiding treatment, compared to traditional risk factor assessment.
